Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

Description of the concentration

By virtue of the notified transaction, EQT Fund Management S.à r.l. (“EFMS”), headquartered and registered in Luxembourg acting as fund manager for and on behalf of the entities forming the investment fund EQT IX, together with The Goldman Sachs Group, Inc. (via funds managed by Goldman Sachs & Co. LLC, a wholly-owned subsidiary of The Goldman Sachs Group, Inc.) (“Goldman Sachs”) intend to indirectly acquire joint control over Parexel International Corporation (“Parexel”) within the meaning of Article 3(1)(b) of the EU Merger Regulation by way of purchase of shares.

EQT IX was launched in July 2020 targeting commitments of approximately EUR 15 billion. EQT IX is an EQT investment fund that seeks to make investments primarily in Europe, with a focus on Northern Europe. EQT IX is a part of the EQT group of private equity funds ultimately owned by EQT AB, which is headquartered in Sweden. EQT IX has appointed EFMS as the alternative investment fund manager of EQT IX. EFMS has exclusive responsibility for the management of EQT IX. The EQT funds’ portfolio companies are active in a variety of industries and sectors. For further information, please see www.eqtgroup.com.

Goldman Sachs is a global investment banking, securities and investment management firm that provides a range of banking, securities and investment services worldwide to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals. For more information, please see www.goldmansachs.com.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. For more information, please see www.parexel.com.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.